Related references
Note: Only part of the references are listed.First results on survival from a large Phase 3 clinical trial of an autologous dendritic cell vaccine in newly diagnosed glioblastoma
Linda M. Liau et al.
JOURNAL OF TRANSLATIONAL MEDICINE (2018)
Current state of immunotherapy for glioblastoma
Michael Lim et al.
NATURE REVIEWS CLINICAL ONCOLOGY (2018)
A phase II trial of autologous dendritic cell vaccination and radiochemotherapy following fluorescence-guided surgery in newly diagnosed glioblastoma patients
Susana Inoges et al.
JOURNAL OF TRANSLATIONAL MEDICINE (2017)
Toxicity and management in CAR T-cell therapy
Challice L. Bonifant et al.
MOLECULAR THERAPY-ONCOLYTICS (2016)
Immune Evasion Strategies of Glioblastoma
Seyed-Mostafa Razavi et al.
FRONTIERS IN SURGERY (2016)
Maintenance Therapy With Tumor-Treating Fields Plus Temozolomide vs Temozolomide Alone for Glioblastoma A Randomized Clinical Trial
Roger Stupp et al.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2015)
A dural lymphatic vascular system that drains brain interstitial fluid and macromolecules
Aleksanteri Aspelund et al.
JOURNAL OF EXPERIMENTAL MEDICINE (2015)
Glioblastoma stem cells and stem cell-targeting immunotherapies
Rogelio Esparza et al.
JOURNAL OF NEURO-ONCOLOGY (2015)
Cerebral lymphatic drainage Implication in the brain immune privilege
Antoine Louveau
M S-MEDECINE SCIENCES (2015)
CANCER IMMUNOTHERAPY Dendritic-cell vaccines on the move
Rachel Lubong Sabado et al.
NATURE (2015)
Two cilengitide regimens in combination with standard treatment for patients with newly diagnosed glioblastoma and unmethylated MGMT gene promoter: results of the open-label, controlled, randomized phase II CORE study
L. Burt Nabors et al.
NEURO-ONCOLOGY (2015)
Revisiting the Mechanisms of CNS Immune Privilege
Antoine Louyeau et al.
TRENDS IN IMMUNOLOGY (2015)
New generation dendritic cell vaccine for immunotherapy of acute myeloid leukemia
Marion Subklewe et al.
CANCER IMMUNOLOGY IMMUNOTHERAPY (2014)
Cilengitide combined with standard treatment for patients with newly diagnosed glioblastoma with methylated MGMT promoter (CENTRIC EORTC 26071-22072 study): a multicentre, randomised, open-label, phase 3 trial
Roger Stupp et al.
LANCET ONCOLOGY (2014)
A Randomized Trial of Bevacizumab for Newly Diagnosed Glioblastoma
Mark R. Gilbert et al.
NEW ENGLAND JOURNAL OF MEDICINE (2014)
Bevacizumab for Newly Diagnosed Glioblastoma Reply
Olivier L. Chinot et al.
NEW ENGLAND JOURNAL OF MEDICINE (2014)
Bevacizumab plus Radiotherapy-Temozolomide for Newly Diagnosed Glioblastoma
Olivier L. Chinot et al.
NEW ENGLAND JOURNAL OF MEDICINE (2014)
Phase I trial of a multi-epitope-pulsed dendritic cell vaccine for patients with newly diagnosed glioblastoma
Surasak Phuphanich et al.
CANCER IMMUNOLOGY IMMUNOTHERAPY (2013)
Therapeutic vaccination against autologous cancer stem cells with mRNA-transfected dendritic cells in patients with glioblastoma
Einar Osland Vik-Mo et al.
CANCER IMMUNOLOGY IMMUNOTHERAPY (2013)
Active immunotherapy using dendritic cells in the treatment of glioblastoma multiforme
Amade Bregy et al.
CANCER TREATMENT REVIEWS (2013)
Dose-Dense Temozolomide for Newly Diagnosed Glioblastoma: A Randomized Phase III Clinical Trial
Mark R. Gilbert et al.
JOURNAL OF CLINICAL ONCOLOGY (2013)
Toll-Like Receptor 4 Engagement Drives Differentiation of Human and Murine Dendritic Cells from a Pro- into an Anti-Inflammatory Mode
Romana Luger et al.
PLOS ONE (2013)
Integration of autologous dendritic cell-based immunotherapy in the standard of care treatment for patients with newly diagnosed glioblastoma: results of the HGG-2006 phase I/II trial
Hilko Ardon et al.
CANCER IMMUNOLOGY IMMUNOTHERAPY (2012)
Signal transducer and activator of transcription 3 promotes angiogenesis and drives malignant progression in glioma
Tiffany A. Doucette et al.
NEURO-ONCOLOGY (2012)
Adjuvant Immunotherapy with Whole-Cell Lysate Dendritic Cells Vaccine for Glioblastoma Multiforme: A Phase II Clinical Trial
Der-Yang Cho et al.
WORLD NEUROSURGERY (2012)
The Next Generation of Glioma Biomarkers: MGMT Methylation, BRAF Fusions and IDH1 Mutations
Andreas von Deimling et al.
BRAIN PATHOLOGY (2011)
Expression of the Stem Cell Marker CD133 in Recurrent Glioblastoma and Its Value for Prognosis
Roberto Pallini et al.
CANCER (2011)
Gene Expression Profile Correlates with T-Cell Infiltration and Relative Survival in Glioblastoma Patients Vaccinated with Dendritic Cell Immunotherapy
Robert M. Prins et al.
CLINICAL CANCER RESEARCH (2011)
IDH testing in diagnostic neuropathology: review and practical guideline article invited by the Euro-CNS research committee
M. Preusser et al.
CLINICAL NEUROPATHOLOGY (2011)
A phase I/II clinical trial investigating the adverse and therapeutic effects of a postoperative autologous dendritic cell tumor vaccine in patients with malignant glioma
Chen-Nen Chang et al.
JOURNAL OF CLINICAL NEUROSCIENCE (2011)
Immune Response in Patients With Newly Diagnosed Glioblastoma Multiforme Treated With Intranodal Autologous Tumor Lysate-dendritic Cell Vaccination After Radiation Chemotherapy
Camilo E. Fadul et al.
JOURNAL OF IMMUNOTHERAPY (2011)
Glioma cancer stem cells induce immunosuppressive macrophages/microglia
Adam Wu et al.
NEURO-ONCOLOGY (2010)
Sipuleucel-T Immunotherapy for Castration-Resistant Prostate Cancer
NEW ENGLAND JOURNAL OF MEDICINE (2010)
Sipuleucel-T Immunotherapy for Castration-Resistant Prostate Cancer.
Philip W. Kantoff et al.
NEW ENGLAND JOURNAL OF MEDICINE (2010)
EXTENT OF RESECTION AND SURVIVAL IN GLIOBLASTOMA MULTIFORME
et al.
NEUROSURGERY (2009)
Analysis of the IDH1 codon 132 mutation in brain tumors
Joerg Balss et al.
ACTA NEUROPATHOLOGICA (2008)
Vaccination elicits correlated immune and clinical responses in glioblastoma multiforme patients
Christopher J. Wheeler et al.
CANCER RESEARCH (2008)
Stem cell marker CD133 affects clinical outcome in glioma patients
Felix Zeppernick et al.
CLINICAL CANCER RESEARCH (2008)
Possible involvement of the M2 anti-inflammatory macrophage phenotype in growth of human gliomas
Y. Komohara et al.
JOURNAL OF PATHOLOGY (2008)
Phase I study of tumor Ag-loaded IL-12 secreting semi-mature DC for the treatment of pediatric cancer
A. M. Dohnal et al.
CYTOTHERAPY (2007)
Results of a Phase II trial of tumor lysate-pulsed dendritic cell vaccination for malignant glioma
JS Yu et al.
NEUROSURGERY (2005)
Dendritic cell vaccination in glioblastoma patients induces systemic and intracranial T-cell responses modulated by the local central nervous system tumor microenvironment
LM Liau et al.
CLINICAL CANCER RESEARCH (2005)
Semi-mature IL-12 secreting dendritic cells present exogenous antigen to trigger cytolytic immune responses
T Felzmann et al.
CANCER IMMUNOLOGY IMMUNOTHERAPY (2005)
Clinical evaluation of dendritic cell vaccination for patients with recurrent glioma: Results of a clinical phase I/II trial
R Yamanaka et al.
CLINICAL CANCER RESEARCH (2005)
MGMT gene silencing and benefit from temozolomide in glioblastoma
ME Hegi et al.
NEW ENGLAND JOURNAL OF MEDICINE (2005)
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma
R Stupp et al.
NEW ENGLAND JOURNAL OF MEDICINE (2005)
Generation of potent anti-tumor immunity in mice by interleukin-12-secreting dendritic cells
KG Huttner et al.
CANCER IMMUNOLOGY IMMUNOTHERAPY (2005)
Vaccination with tumor lysate-pulsed dendritic cells elicits antigen-specific, cytotoxic T-cells in patients with malignant glioma
JS Yu et al.
CANCER RESEARCH (2004)
The use of dendritic cells in cancer immunotherapy
G Schuler et al.
CURRENT OPINION IN IMMUNOLOGY (2003)
Naive CD8(+) T cell recruitment and proliferation are dependent on stage of dendritic cell maturation
A Kaiser et al.
EUROPEAN JOURNAL OF IMMUNOLOGY (2003)
Monocyte enrichment from leukapharesis products for the generation of DCs by plastic adherence, or by positive or negative selection
T Felzmann et al.
CYTOTHERAPY (2003)
Decoding the patterns of self and nonself by the innate immune system
R Medzhitov et al.
SCIENCE (2002)
Kinetics of dendritic cell activation:: impact on priming of TH1, TH2 and nonpolarized T cells
A Langenkamp et al.
NATURE IMMUNOLOGY (2000)
Share Paper
